65,437 trials
Healthy
Primary: Change in Visual Analogue Scale (VAS) of Anxiety - From Baseline to 2 Hours — 0.5; 0.0 units on a scale
Encephalitis, Japanese B
Primary: Seroconversion Rate After Primary Vaccination — 100 percentage of seroconversion
Wheelchair Users
Primary: Oxygen Consumption — 625 VO2 (ml/min)
Diabetic Peripheral Neuropathy
Primary: Average Diabetic Peripheral Neuropathy (DPN) Pain Based on a Numeric Rating Scale (NRS) Over the Last 7 Days of Each Treatment Period (Week 6 of Each Treatment Period)…
Meningitis · Meningococcal Infection
Primary: Number of Participants Achieving Antibody Titers ≥1:8 Against Meningococcal Serogroups A, C, Y, and W-135 by Serum Bactericidal Assay Using Human Complement Following…
Hyperphosphatemia · End-stage Renal Disease · Renal Failure Chronic Requiring Hemodialysis
Primary: The Primary Outcome of This Trial Will be the Change in Serum Phosphorus From Baseline to End of Treatment After a Four Week Treatment Period. — -1.53 mg/dL
Other and Unspecified Complications of Amputation Stump
Primary: 75 Meter Self Selected Walking Test — 65.1; 64.0; 54.0 seconds
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline — 0.03; -0.07; -0.13; 0.22 percentage points — p=0.044
Degenerative Disc Disease
Primary: Reduction of Disability at 6 Months Versus Baseline Using the Oswestry Disability Index (ODI) — -25.4 units on a scale — p=<0.0001
Neutrophilic Asthma
Primary: Number of Participants Who Maintained an Absolute Peripheral Blood Neutrophil Count >=1500/µL — 20; 12 Number of participants
Asthma
Primary: Maximum Percent Drop From Pre-allergen Baseline in Forced Expiratory Volume in 1 Second (FEV1) for Late-Phase Asthma Response (LAR) at Screening — 27.19; 20.47 percent…
Contraception
Primary: Venous Thromboembolism (VTE); Hazard Ratio for DRSP-24 Day vs. Non-DRSP OCs — 19; 16; 101; 7 participants
Atrial Fibrillation
Primary: Documented Recurrence of Atrial Fibrillation/Atrial Flutter — 59; 47 percentage of participants
Otitis Media
Primary: Percentage of Ears Treated Successfully With the TTDS in the Absence of Acute Intraprocedural Adverse Events. — 94.6 percentage of ears
Malaria, Falciparum · Malaria, Vivax
Primary: Derived Parasite Reduction Rate at 24 Hours (PPR24) — 1.38; 1.56; 1.71; 1.63 Log10 parasites/24h — p=0.01